Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa, Open-label, Multicenter Study of the Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide to Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

NCT05950165 is registered in ClinicalTrials.gov with Cho Pharma Inc. as lead sponsor.

NCT NCT05950165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05950165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa, Open-label, Multicenter Study of the Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide to Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
Lead sponsor
Cho Pharma Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 15, 2020
Completion date
December 23, 2026
Enrollment
37 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma